Latest News

Tiziana Announces Positive Qualitative Six-Month PET Scan Results With Intranasal Foralumab Treating Multiple Sclerosis Patients Diagnosed With Non-Active Secondary Progressive MS (na-SPMS)

13 October 2023

  • Five out of six patients in FDA authorized Expanded Access Program are showing a qualitative reduction in microglia activation (a key biomarker being observed)
  • Foralumab to advance into Phase 2 human clinical trials...

Read more

Tiziana Announces Presentation of Six-Month Safety and Biomarker Data for Intranasal Foralumab in Patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) at the ECTRIMS Annual Congress

11 October 2023

  • Late-breaking poster to be presented titled: “Treatment Of Six Non-Active Secondary Progressive MS With Nasal Anti-CD3 Monoclonal Antibody (Foralumab): Safety, Biomarker, And Disability Outcomes”

NEW YORK, October 11, 2023 -- Tiziana Life Sciences...

Read more

Tiziana Life Sciences Initiates Multi-Center Phase 2a Clinical Trial of Intranasal Foralumab for Non-Active Secondary Progressive Multiple Sclerosis

26 September 2023

NEW YORK, September 26, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of delivery, today announced that it held an Investigator’s Meeting with principal investigators...

Read more

MEDIA: BioWorld: Nasal anti-CD3 antibody improves Alzheimer’s disease in mice

12 September 2023

Sep. 12, 2023

By Mar de Miguel

Alzheimer’s disease (AD) has a new candidate for its treatment. Nasal anti-CD3 monoclonal antibody (MAb) reduced microglia activation in the brain of mice without its effect being dependent on the β-amyloid (Aβ) deposits characteristic...

Read more

Tiziana Life Sciences to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

08 September 2023

NEW YORK, September 8, 2023 – Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that the Company will virtually present and host...

Read more

Study Validating MoA of Intranasal Foralumab in Alzheimer’s Disease Published in the Prestigious Journal PNAS, Following FDA IND Clearance

06 September 2023

  • The authors conclude that “nasal anti-CD3 has the potential to be a non-toxic novel immunotherapeutic approach for the treatment of Alzheimer’s disease (AD)”
  • FDA has cleared the IND for...

Read more

Tiziana Life Sciences Announces Appointment of William A. Clementi as Chief Development Officer

23 August 2023

  • Leadership Addition Strengthens Company's Commitment to Advancing Innovative Therapies

NEW YORK, August 23, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies...

Read more

Tiziana Life Sciences Announces Foralumab Presentation by Dr. Howard Weiner at the Annual Meeting of the International Society of Neuroimmunology

23 August 2023

NEW YORK, August 23 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced an oral presentation of “Nasal anti-CD3 mAb induces...

Read more

Tiziana Life Sciences Announces Live Bloomberg TV Interview of Renowned Scientist Dr. Howard L. Weiner to Discuss FDA IND Clearance for Intranasal Foralumab in Alzheimer's Disease

17 August 2023

Read more

Media: Neurology Live Coverage: FDA Clears IND to Test Intranasal Foralumab in Alzheimer Disease

16 August 2023

FDA Clears IND to Test Intranasal Foralumab in Alzheimer Disease

Aug 15, 2023

Isabella Ciccone, MPH

Foralumab, a therapy designed to bind to T cell receptor, is about to be assessed in phase 2 trials of patients with non-active secondary progressive multiple...

Read more

Page 2 of 30 Previous Next